Hookipa Capital Surpluse from 2010 to 2025

HOOK Stock  USD 1.23  0.02  1.65%   
Hookipa Pharma Capital Surpluse yearly trend continues to be quite stable with very little volatility. The value of Capital Surpluse is projected to decrease to about 230.1 M. From the period between 2010 and 2025, Hookipa Pharma, Capital Surpluse regression line of its data series had standard deviation of  178,433,485 and standard deviation of  178,433,485. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-12-31
Previous Quarter
457 M
Current Value
230.1 M
Quarterly Volatility
178.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Hookipa Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hookipa Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 3.9 M, Interest Income of 3.9 M or Depreciation And Amortization of 2.9 M, as well as many indicators such as Price To Sales Ratio of 8.5, Dividend Yield of 0.0 or PTB Ratio of 0.64. Hookipa financial statements analysis is a perfect complement when working with Hookipa Pharma Valuation or Volatility modules.
  
Check out the analysis of Hookipa Pharma Correlation against competitors.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.

Latest Hookipa Pharma's Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Hookipa Pharma over the last few years. It is Hookipa Pharma's Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Hookipa Pharma's overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Hookipa Capital Surpluse Regression Statistics

Arithmetic Mean147,292,520
Geometric Mean21,140,440
Coefficient Of Variation121.14
Mean Deviation162,837,210
Median3,327,000
Standard Deviation178,433,485
Sample Variance31838.5T
Range454.5M
R-Value0.85
Mean Square Error9543.8T
R-Squared0.72
Significance0.000032
Slope31,806,579
Total Sum of Squares477577.6T

Hookipa Capital Surpluse History

2025230.1 M
2024457 M
2022397.3 M
2021317.1 M
2020309.3 M
2019225.6 M
20183.3 M

About Hookipa Pharma Financial Statements

Hookipa Pharma investors utilize fundamental indicators, such as Capital Surpluse, to predict how Hookipa Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Capital Surpluse457 M230.1 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Hookipa Pharma is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Hookipa Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Hookipa Pharma Stock. Highlighted below are key reports to facilitate an investment decision about Hookipa Pharma Stock:
Check out the analysis of Hookipa Pharma Correlation against competitors.
For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.47)
Revenue Per Share
3.505
Quarterly Revenue Growth
(0.82)
Return On Assets
(0.23)
Return On Equity
(0.62)
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.